`
`WORLD INTELLECTUAL PROPERTY ORGANIZATION
`International Bureau
`
`
`
`INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`
` (51) International Patent Classification 6 i
`
`C07D 207/00, 401/00, C07K 5/00
`
`(11) International Publication Number:
`
`W0 98/19998
`
`A2
`
`_
`.
`‘
`(43) International Publication Date:
`
`14 May 1998 (14.05.98)
`
`(21) International Application Number:
`
`PCT/EP97/06l25
`
`(22) International Filing Date:
`
`5 November 1997 (05.11.97)
`
`(30) Priority Data:
`08/746,295
`
`7 November 1996 (07.11.96)
`
`US
`
`(71) Applicant (for all designated States except US): NOVARTIS
`AG [CH/CH]; Schwarzwaldallee 215, CPI—4058 Basel (CH).
`
`(72) Inventor; and
`(for US only): VILLHAUER, Edwin,
`(75) Inventor/Applicant
`Bernard [US/US];
`20 Dorothy Drive, Morristown, NJ
`07960 (US).
`
`(74) Agent: ROTH, Bernhard, M.; Novartis AG, Patent— und
`Markenabteilung, Lichtstrasse 35, CH~4002 Basel (CH).
`
`(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
`BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, Fl, GB, GE,
`GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
`LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
`NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
`TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH,
`KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ,
`BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
`CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
`PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
`ML, MR, NE, SN, TD, TG).
`
`Published
`
`Without international search report and to be republished
`upon receipt of that report.
`
`
`
`(54) Title: N—SUBSTITUTED 2—CYANOPYRROLIDINES
`
`(57) Abstract
`
`the
`N—(N’—substituted glycyl)—2—cyanopyrrolidines, e.g.
`compounds of formula (I) wherein R has various significances, are
`novel. They inhibit DPP—IV (dipeptidyl—peptidase—IV) activity.
`They are therefore indicated for use as pharmaceuticals in inhibiting
`DPPAIV and in the treatment of conditions mediated by DPP—IV,
`such as non—insulin—dependent diabetes mellitus, arthritis, obesity,
`osteoporosis and further conditions of impaired glucose tolerance.
`
`
`
`/
`
`[I]
`
`MYLAN - EXHIBIT 1008
`
`MYLAN - EXHIBIT 1008
`
`
`
`FOR THE PURPOSES OF INFORMATION ONLY
`
`Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.
`
`Singapore
`
`Albania
`Armenia
`Austria
`Australia
`Azerbaijan
`Bosnia and Herzegovina
`Barbados
`Belgium
`Burkina Faso
`Bulgaria
`Benin
`Brazil
`Belarus
`Canada
`Central African Republic
`Congo
`Switzerland
`Cate d’Ivoire
`Cameroon
`China
`Cuba
`Czech Republic
`Germany
`Denmark
`Estonia
`
`ES
`FI
`FR
`GA
`GB
`GE
`GH
`GN
`GR
`HU
`IE
`
`IS
`IT
`JP
`KE
`KG
`KP
`
`KR
`
`LC
`LI
`LK
`
`Spain
`Finland
`France
`Gabon
`United Kingdom
`Georgia
`Ghana
`Guinea
`Greece
`Hungary
`Ireland
`Israel
`Iceland
`Italy
`Japan
`Kenya
`Kyrgyzstan
`Democratic People’s
`Republic of Korea
`Republic of Korea
`Kazakstan
`Saint Lucia
`Liechtenstein
`Sri Lanka
`Liberia
`
`LS
`LT
`LU
`LV
`MC
`
`Lesotho
`Lithuania
`Luxembourg
`Latvia
`Monaco
`Republic of Moldova
`Madagascar
`The former Yugoslav
`Republic of Macedonia
`Mali
`Mongolia
`Mauritania
`Malawi
`Mexico
`Niger
`Netherlands
`Norway
`New Zealand
`Poland
`Portugal
`Romania
`Russian Federation
`Sudan
`Sweden
`
`SI
`SK
`SN
`SZ
`TD
`TG
`TJ
`TM
`TR
`TT
`UA
`UG
`US
`UZ
`VN
`YU
`ZW
`
`Slovenia
`Slovakia
`Senegal
`Swaziland
`Chad
`Togo
`Tajikistan
`Turkmenistan
`Turkey
`Trinidad and Tobago
`Ukraine
`Uganda
`United States of America
`Uzbekistan
`Viet Nam
`Yugoslavia
`Zimbabwe
`
`
`
`W0 98/ 19998
`
`PCT/EP97/06125 _
`
`N -SUBSTITUTED 2-CYANOPYRROLIDINES
`
`
`Field
`
`The present invention relates to N-substituted 2-cyanopyrrolidines. More particularly,
`
`it provides novel N—glycyl—Z—cyanopyrrolidine derivatives.
`
`Mam
`
`Dipeptidyl peptidase-IV (DPP-IV) is a serine protease which cleaves N—terminal
`
`dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate
`
`position. Although the biological role of DPP-IV in mammalian systems has not been
`
`completely established, it is believed to play an important role in neuropeptide metabolism,
`
`T-cell activation, attachment of cancer cells to the endothelium and the entry of HIV into
`
`lymphoid cells. DPP-IV is responsible for inactivating glucagon-like peptide-1 (GLP-l).
`
`More particularly, DPP—IV cleaves the amino-terminal His—Ala dipeptide of GLP—1, generating
`
`a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-l. Since
`
`the half-life for DPP—IV cleavage is much shorter than the half—life for removal of GLP-1 from
`
`circulation, a significant increase in GLP-l bioactivity (5- to 10-fold) is anticipated from
`
`DPP-IV inhibition. Since GLP-1 is a major stimulator of pancreatic insulin secretion and has
`
`direct beneficial effects on glucose disposal, DPP-IV inhibition appears to represent an
`
`attractive approach for treating non-insulin-dependent diabetes mellitus (NIDDM).
`
`Although a number of DPP-IV inhibitors have been described, all have limitations
`
`relating to potency, stability or toxicity. Accordingly, a great need exists for novel DPP—IV
`
`inhibitors which are useful in treating conditions mediated by DPP-IV inhibition and which do
`
`not suffer from the above-mentioned limitations.
`
`
`
`W0 98/ 19998
`
`PCT/EP97/06125 _
`
`Summagx of the invention
`
`The invention provides novel N—(N’—substituted g]ycy1)-2—cyanopyrrolidines which are
`
`effective as DPP-IV inhibitors in treating conditions mediated by DPP-IV. It also concerns
`
`corresponding pharmaceutical compositions, a process for their preparation, a method of
`
`inhibiting DPP-IV comprising administering to a patient in need of such treatment a
`
`therapeutically effective amount thereof, the compounds for use as a pharmaceutical, and their
`
`use in a process for the preparation of a medicament for treating a condition mediated
`
`by DPP-IV.
`
`Detailed description
`
`The invention concerns N-(N’-substituted glycyl)-2-cyanopyrrolidines, hereinafter
`
`briefly named "the compounds of the invention"; more particularly, it concerns compounds
`
`of formula I:
`
`wherein R is:
`
`a) R1R13N(CH2)m- wherein
`
`R1 is a pyridinyl or pyrimidinyl moiety optionally mono- or independently
`
`disubstituted with (C1-4)alky1, (C1-4)alkoxy, halogen, trifluoromethyl,
`
`cyano or nitro; or phenyl optionally mono- or independently disubstituted
`
`with (CM)alkyl, (C1-4)alkoxy or halogen;
`
`R1,, is hydrogen or (C1-g)alkyl; and
`
`m is 2 or 3;
`
`b) (C3.1z)cycloalkyl optionally monosubstituted in the 1-position with (C1.3)hydroxyalkyl;
`
`c) R2(CH2)..- wherein either
`
`R2 is phenyl optionally mono- or independently di- or independently trisubstituted
`
`with (C14)alkyl, (CM)alkoxy, halogen or phenylthio optionally monosubstituted
`
`in the phenyl ring with hydroxymethyl; or is (C1-g)alkyl; a [3.1.1]bicyclic
`
`carbocyclic moiety optionally mono— or plurisubstituted with (C1-s)a1kyl;
`
`
`
`wo 98/19998
`
`PCT/EP97/06125 a
`
`-3-
`
`a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted
`
`with (CM)a1kyl, (C14)alkoxy or halogen; cyclohexene; or adamantyl; and
`
`n is 1 to 3; or
`
`R2 is phenoxy optionally mono— or independently disubstituted with (CM)alkyl,
`
`(C14)alkoxy or halogen; and
`
`n is 2 or 3;
`
`d) (R3)2CH(CH2)2- wherein each R3 independently is phenyl optionally mono- or
`
`independently disubstituted with (CM)alkyl,
`
`(CM)alkoxy or halogen;
`
`e) R4(CH2)P- wherein R4 is 2-oxopyrrolidinyl or (C2.4)alkoxy and
`
`p is 2 to 4;
`
`f) isopropyl optionally monosubstituted in 1-position with (C,.3)hydroxyalkyl;
`
`g) R5 wherein R5 is:
`
`indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with
`
`benzyl; a [2.2.1]— or [3.1.1]bicyclic carbocyclic moiety optionally mono- or
`
`plurisubstituted with (C;-8)alkyl; adamantyl; or (C1-g)alkyl optionally mono- or
`
`independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono-
`
`or independently disubstituted with (C1.4)alkyl, (CM)alkoxy or halogen;
`
`in free form or in acid addition salt form.
`
`The compounds of formula I can exist in free form or in acid addition salt form. Salt
`
`forms may be recovered from the free form in known manner and vice—versa. Acid addition
`
`salts may e.g. be those of pharmaceutically acceptable organic or inorganic acids. Although
`
`the preferred acid addition salts are the hydrochlorides, salts of methanesulfonic, sulfuric,
`
`phosphoric, citric, lactic and acetic acid may also be utilized.
`
`The compounds of the invention may exist in the form of optically active isomers or
`
`diastereoisomers and can be separated and recovered by conventional techniques, such as
`
`chromatography.
`
`"Alkyl" and "alkoxy" are either straight or branched chain, of which examples of the
`
`latter are isopropyl and tert-butyl.
`
`R preferably is a), b) or e) as defined above. R1 preferably is a pyridinyl or pyrimidinyl
`
`moiety optionally substituted as defined above. R1,, preferably is hydrogen. R2 preferably is
`
`phenyl optionally substituted as defined above. R3 preferably is unsubstituted phenyl.
`
`
`
`W0 98/ 19998
`
`PCT/EP97/06125 _
`
`-4-
`
`R4 preferably is alkoxy as defined above. R5 preferably is optionally substituted alkyl as defined
`
`above. m preferably is 2. n preferably is 1 or 2, especially 2. p preferably is 2 or 3,
`
`especially 3.
`
`Pyridinyl preferably is pyridin-2—yl; it preferably is unsubstituted or monosubstituted,
`
`preferably in 5-position. Pyrimidinyl preferably is pyrimidin-Z-yl. It preferably is unsubstituted
`
`or monosubstituted, preferably in 4—position. Preferred as substitutents for pyridinyl and
`
`pyrimidinyl are halogen, cyano and nitro, especially chlorine.
`
`When it is substituted, phenyl preferably is monosubstituted; it preferably is substituted
`
`with halogen, preferably chlorine, or methoxy. It preferably is substituted in 2-, 4— and/or
`
`5-position, especially in 4-position.
`
`(C3_lg)cycloalkyl preferably is cyclopentyl or cyclohexyl. When it is substituted, it
`
`preferably is substituted with hydroxymethyl.
`
`(C1-4)alkoxy preferably is of 1 or 2 carbon
`
`atoms, it especially is methoxy.
`
`(C2-4)alkoxy preferably is of 3 carbon atoms, it especially is
`
`isopropoxy. Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or
`
`bromine, especially chlorine. (C1.g)alkyl preferably is of 1 to 6, preferably 1 to 4 or 3 to 5,
`
`especially of 2 or 3 carbon atoms, or methyl. (C14) alkyl preferably is methyl or ethyl,
`
`especially methyl. (C1.3)hydroxyalkyl preferably is hydroxymethyl.
`
`A [3.1 .1]bicyclic carbocyclic moiety optionally substituted as defined above preferably
`
`is bicyclo[3.1.l]hept-2-yl optionally disubstituted in 6-position with methyl, or
`
`bicyclo[3.1.l]hept—3-y1 optionally trisubstituted with one methyl in 2-position and two methyl
`groups in 6—position. A [2.2.1]bicyclic carbocyclic moiety optionally substituted as defined
`
`above preferably is bicyclo[2.2.1]hept-2—yl.
`
`Naphthyl preferably is 1-naphthy1. Cyclohexene preferably is cyclohex-l-en—l-yl.
`
`Adamantyl preferably is l- or 2-adamantyl.
`
`A pyrrolidinyl or piperidinyl moiety optionally substituted as defined above preferably is
`
`pyrrolidin-3-yl or piperidin-4-y]. When it is substituted it preferably is N—substituted.
`
`
`
`WO 98/19998
`
`PCT/EP97/06125 -
`
`-5-
`
`A preferred group of compounds of the invention is the compounds of formula I
`
`wherein R is R’ (compounds Ia), whereby R’ is:
`
`- R1 ’NH(CH2)2- wherein R1 ’ is pyridinyl optionally mono- or independently disubstituted with
`
`halogen, trifluoromethyl, cyano or nitro; or unsubstituted
`
`pyrirnidinyl;
`
`-
`
`(C3_7)cycloalky1 optionally monosubstituted in 1-position with (C1_3)hydroxyalkyl;
`
`— R4’(CH2)3— wherein R4’ is (C24)alkoxy; or
`
`- R5, wherein R5 is as defined above;
`
`in free form or in acid addition salt form.
`
`More preferred compounds of the invention are those compounds of formula I wherein
`
`R is R" (compounds Ib), whereby R" is:
`
`- R1"NH(CH2)2- wherein R1" is pyridinyl mono— or independently disubstituted with halogen,
`
`trifluoromethyl, cyano or nitro;
`
`-
`
`(C4_6)cycloalky1 monosubstituted in 1—position with (C1_3)hydroxyalkyl;
`
`- R4’(CH2)3- wherein R4’ is as defined above; or
`
`- R5’ wherein R5’ is a [2.2.1]— or [3.1.1]bicyclic carbocyclic moiety optionally mono— or
`
`plurisubstituted with (C 1-8)a1ky1; or adamantyl;
`
`in free form or in acid addition salt form.
`
`Even more preferred compounds of the invention are the compounds of formula I wherein
`
`R is R"’ (compounds Ic), whereby R"’ is:
`
`- R;"NH(CH2)2- wherein R1" is as defined above;
`
`-
`
`(C4_6)cycloalky1 monosubstituted in 1-position with hydroxymethyl;
`
`- R4’(CH2)3- wherein R4’ is as defined above; or
`
`- R5" wherein R5" is adamantyl;
`
`in free form or in acid addition salt form.
`
`
`
`W0 98/19998
`
`PCT/EP97/06125 _
`
`-6-
`
`A further group of compounds of the invention is compounds Ip, wherein R is R”,
`
`which is:
`
`a) RIPNH(CH2)2- wherein Rl" is a pyridinyl or pyrimidinyl moiety optionally mono- or
`
`independently disubstituted with halogen, trifluoromethyl,
`
`cyano or nitro;
`
`b) (C3.7)cycloalkyl optionally monosubstituted in 1-position with (C1-3)hydroxyalky];
`
`c) R2P(CH2)2- wherein R2” is phenyl optionally mono- or independently di- or independently
`
`d)
`
`(R3p)2CH(CH2)2- wherein each R3p independently is phenyl optionally monosubstituted with
`
`trisubstituted with halogen or (C1.3)alkoxy;
`
`halogen or (C1-3)alkoxy;
`
`e) R4(CH2)3- wherein R4 is as defined above; or
`
`f) isopropyl optionally monosubstituted in 1-position with (C1_3)hydroxyalkyl;
`
`in free form or in pharmaceutically acceptable acid addition salt form.
`
`A further group of compounds of the invention is compounds Is, wherein R is RS,
`
`which is:
`
`a) RlsRlaS(CH2)ms- wherein R15 is pyridinyl optionally mono- or independently disubstituted
`
`with chlorine, trifluoromethyl, cyano or nitro; pyrimidinyl
`
`optionally monosubstituted with chlorine or trifluoromethyl;
`
`or phenyl;
`
`R1: is hydrogen or methyl; and
`
`ms is 2 or 3;
`
`b)
`
`(C3_1z)cycloalkyl optionally monosubstituted in 1-position with hydroxymethyl;
`
`c) R25(CH2)m- wherein either
`
`R25 is phenyl optionally mono- or independently di- or independently
`
`trisubstituted with halogen, alkoxy of l or 2 carbon atoms or
`
`phenylthio monosubstituted in the phenyl ring with hydroxymethyl;
`
`(C1-5)alkyl; 6,6-dimethylbicyclo[3. 1 . 1]hept-2—yl; pyridinyl;
`
`naphthyl; cyclohexene; or adamantyl; and ms is 1 to 3; or
`
`R28 is phenoxy; and ns is 2;
`
`d) (3,3-diphenyl)propyl;
`
`
`
`WO 98/19998
`
`PCT/EP97/06125 _
`
`-7-
`
`e) R45(CH2)ps wherein R45 is 2-oxopyrrolidin-1-yl or isopropoxy and
`
`ps is 2 or 3;
`
`f) isopropyl optionally monosubstituted in 1~position with hydroxymethyl;
`
`g) R5s wherein R55 is:
`
`indanyl; a pyrrolidinyl or piperidinyl moiety optionally N-substituted
`
`with benzyl; bicyclo[2.2.1]hept-2-yl; 2,6,6-trimethylbicyclo—
`
`[3.1.1]hept-3-yl; adamantyl; or (C1-g)alkyl optionally mono- or
`
`independently disubstituted with hydroxy, hydroxymethyl or phenyl;
`
`in free form or in acid addition salt form.
`
`The compounds of the invention may be prepared by a process which comprises
`
`coupling a reactive (2-cyanopyrrolidino)carbonylmethylene compound with an appropriate
`
`substituted amine; more particularly, for the preparation of the compounds of formulaI it
`
`comprises reacting a compound of formula H
`
`II
`
`O H
`
`C
`
`\‘\\\CN
`V ‘53
`
`X
`
`wherein X is a reactive group,
`
`with a compound of formula III
`
`wherein R is as defined above,
`
`NH2R
`
`III
`
`and recovering the resultant compound of formula I in free form or in acid addition salt form.
`
`X preferably is a halogen such as bromine, chlorine or iodine.
`
`The process of the invention may be effected in conventional manner.
`
`The compound of formula II is preferably reacted with at least 3 equivalents of a
`
`primary amine of formula III. The reaction is conveniently conducted in the presence of an
`
`inert, organic solvent, preferably a cyclic ether such as tetrahydrofuran. The temperature
`
`preferably is of from about 0° to about 35°C, preferably between about 0° and about 25°C.
`
`The compounds of the invention may be isolated from the reaction mixture and purified
`
`in conventional manner, e.g. by chromatography.
`
`
`
`wo 98/19998
`
`PCT/EP97/06125 t
`
`-3-
`
`The starting materials may also be prepared in conventional manner.
`
`The compounds of formula 11 may e.g. be prepared by the following two-step reaction
`
`scheme:
`
`fl:
`H-N: ]
`
`NH2
`
`
`STEP 1
`
`
`STEP 2
`
`X
`
`0
`
`§ \NH2
`ll
`i)
`X \/C\N '
`C
`\/ \ x L, 11
`Et3N, DMAP
`(at least 2 eq.)
`
`IV
`
`V
`
`Step 1 involves the reaction of the pyrrolidine of formula IV with a slight molar excess
`
`of a haloacetylhalide such as bromoacetylbromide or chloroacetylchloride and triethylamine
`
`and a catalytic amount of dimethylaminopyridine (DMAP). The reaction conveniently is
`
`conducted in the presence of an inert, organic solvent, preferably a chlorinated, aliphatic
`
`hydrocarbon such as methylene chloride, at a temperature of from about 0° to about 25°C,
`
`preferably at a temperature between about 0° and about 15°C.
`
`Step 2 concerns the dehydration of the compound of formula V, prepared in Step 1,
`
`with at least 2 equivalents of trifluoroacetic anhydride (TFAA). The dehydration preferably is
`
`conducted in the presence of an inert, organic solvent such as tetrahydrofuran or a chlorinated,
`
`aliphatic hydrocarbon such as methylene chloride, at a temperature of from about 0° to about
`
`25°C, preferably at a temperature between about 0° and about 15°C.
`
`Insofar as its preparation is not particularly described herein, a compound used as
`
`starting material is known or may be prepared from known compounds in known manner or
`
`analogously to known methods or analogously to methods described in the Examples.
`
`
`
`WO 98/19998
`
`PCT/EP97/06125 _
`
`The following Examples illustrate the invention. All temperatures are in degrees
`
`Celsius.
`
`-9-
`
` Example 1: 1- 2-
`
`(S z-pyrrolidine
`
`To a 500 ml flask is added 16.6 g of 2-[(5-chloropyridin-2-yl)amino]ethylamine and
`
`100 m1 of tetrahydrofuran and the mixture is cooled in an ice bath. To the cooled mixture is
`
`added 7.0 g of (2-cyanopyrrolidino)carbonylmethylene-(S)-bromide dissolved in 30 ml of
`
`tetrahydrofuran. The resultant mixture is stirred for 2 hours at 0°, the solvent is removed by
`
`rotovaping and the mixture is partitioned between ethyl acetate and water. The product is then
`
`extracted into the ethyl acetate layer and the aqueous layer is then washed twice with ethyl
`
`acetate. The combined organic layers are washed successively with water and brine, dried over
`
`sodium sulfate and concentrated to obtain the desired free base compound in crude form. The
`
`crude form is then purified on silica gel employing a mixture of 5% methanol in methylene
`
`chloride as the eluent to yield the title compound in free base form as a light brown oi].
`
`After dissolving the free base in 30 ml of dry tetrahydrofuran, hydrogen chloride gas
`
`is bubbled into the solution for five seconds. The off-white precipitate that forms is filtered,
`
`washed with dry tetrahydrofuran and the solvent is removed by high vacuum pumping to
`
`obtain the title compound in dihydrochloride acid addition salt form (off-white solid;
`
`mp. 265°—267°; NMR: see * at bottom of Table hereunder).
`
`The starting material is obtained as follows:
`
`a) 22.37 g of (S)-2-carbamoylpyrrolidine, 30.1 ml of triethylamine and 30.0 mg of
`
`dimethylaminopyridine (DMAP) are dissolved in 200 ml of methylene chloride and the solution
`
`is then added, dropwise, to an ice-cold solution of 18.8 ml of bromoacetylbromide in 192 ml
`of methylene chloride, over a period of 60 minutes under a calcium sulfate drying tube. The
`
`resultant solution is stirred for 2 hours at ice-water temperature under a calcium sulfate drying
`
`tube, then poured into 3.5 liters of ethyl acetate. The resultant precipitate is filtered, washed
`
`with ethyl acetate, and the filtrate is concentrated to obtain (2-carbamoylpyrrolidino)-
`
`carbonylmethylene-(S)-bromide (hard yellow taffy).
`
`
`
`W0 98/19998
`
`PCT/EP97/06125 _
`
`-10-
`
`b) 50.0 g of the bromide compound prepared in a) above is dissolved in 300 ml of methylene
`
`chloride and the solution is cooled in an ice water bath under a calcium sulfate drying tube.
`
`The cooled solution is then poured into 60.2 ml of trifluoroacetic anhydride over a 2 minute
`
`period, the resultant solution is stirred at ice-water temperature under a calcium sulfate drying
`
`tube for 4 hours, and partitioned between methylene chloride and saturated aqueous sodium
`
`bicarbonate. The product is extracted into the methylene chloride layer and the aqueous layer
`
`is washed twice with methylene chloride. The combined organic
`
`layers are washed successively with water and brine and then dried over sodium sulfate. The
`
`solution is filtered and the solvent is removed by rotovaping and high vacuum pumping to
`
`obtain (2-cyanopyrrolidino)carbonylmethylene-(S)-bromide (dark yellow solid).
`
`
`
`WO 98/19998
`
`PCT/EP97/06125
`
`—11
`
`
`
`
`
`We@5888wEwcommotcom@5823SEE:maomoficmE3:8502aA«BEENodonagfi2:we35:09:00MERE—8use
`
`
`
`
`
`
`
`E022.Nsdus0N:-"2&3
`
`
`
`
`
`
`
`
`
`”*mzz”0%32as.3336on253%Nfin
`
`
`
`
`
`.02.xm0“.OZ
`
`=o52a._aEcoFEE.“23-52:.35?m:.Nm:32M:052%aaEESEEN.Neaiaéo.m:.NN
`
`
`
`
`
`8%coszCBQEEUbmsowoficxx8.5mmoEENxm
`
`
`
`
`
`2:mocczomEooawe8.5%:3.5363EomSN3:0205%JEFFwagozoufl2:EV533:8wevasomEoowcmwcommotoom5:»E3258
`
`
`
`
`
`”C02055:202502:3093RE2:8on@2382Ecczomfioo2:£055.58mm85:02:
`
`E22”023:45“28233N:0
`
`
`
`E226:852NnEBEEEENN.52522825.3:5E22”so52%AmNn:50,35533-522:-Ne*mzz€98.956:8as?iaa.N-EuQOEEESEQEuE-cm*mzz”so82%ENa.33EEEENNEEEEE:.Nv
`
`*mzz”:052%Naa...».cEEENNeEHEEBfi.2-NE.
`
`*mzzNnEiafifieozuNYNEE22:652%Na.23.2:EwarNe=zE=Eamo-§.Nup
`
`*mEzM:052%3MNa.2:EssaiNestaéo.m-eo___o.m:-N§*mzzHEis322ENEama.33€553»Naacaei.a_-Na*mzzNaEoéaaoifimdE.
`
`
`
`*mzzME5%»3mNa3.5»EgaacrNeataamo-0_.Nma
`
`322:652%3mNn.2:35:52»Naetaeefic.we:UN
`
`26m:8N334-33295A:
`
`E22:6N25.323EN:3%amaEiififixefiaa-35:53-3.N=232E8233Nno.
`
`=o2305~gEacuafixcmemcmséNu
`
`
`
`WO 98/19998
`
`
`
`
`
`1A55325:”222-0:”06:3:.356:830:0:5w:_:055202350553550.5533S_A55332U522.0:
`
`
`
`
`o...:553535:“222-02”03-8:.356:830:0:5::::05:205:2055fiééea
`
`”032-5:.356:8253_:05:225:055355056YNa:
`
`
`
`5&38.2:”222-0:6:835:253.50_:05:83:52:5.
`
`
`
`
`$22-02memodd:”5:8.033330:9»6:nExoaofihoifiufimxgaa.ama”237%:356:8253::0_:::0§:0:%30::0-$-~3SEE3w:A55322“222-02MORE:356:8253.503::06555552-233.550555%-:S5&3is”222-02
`
`
`
`
`
`
`
`
`
`
`.OZ.xm9.OZ
`
`3:226:8:2_:0
`
`=0sou—omama$38.5».~.:_E_P_.§Qoxc-mv-m33:326:8:38:_:0
`
`:052:05cm:5523:2055.1:338:232
`
`
`
`
`
`.5&3EN:“22262558325-8.356:8253::0655830555235053235:3.-mNa
`
`
`
`
`
`8%50325582220bmsowoficlxatomm295me
`
`
`
`”.535.356:8253_:05250:2030E533EN:”222$:55:3:.356:8253::05.5202:5055355055663.Nmm
`
`
`
`
`.2.:20.030555055563.252333.35:35:36.a:”222-0:
`
`
`“2226:”03233356835:253_:05030:5030mu“222-02:Nm:553mg:”08;:"08.3.356:82535:065:20:3555535:mm553:3:.356:8253a::053-305.330.055.2533988%:"052.32_.z.H.m.20305550558333:5mfmvamduazm:mmm5:323“222-0:$2.65:.356:8253::03555555536anm:5536.5”222.02.356:8253_:06552085553505333m533m.5“222.0:
`
`
`
`
`
`
`
`
`
`
`
`
`
`”222-0:x0233858.356:8253a::05555:3330:A53385:”222-0:”2332.356:835:25355_:05:225.:-:020:0_0:0-:-~R:5532.3_”222.0:“05.3.356:835:253_:05:225:055555055.3335:3:3:
`
`
`
`
`
`
`
`
`
`
`
`
`:553m.5N222.0:”063%356:8253a::05-350:
`
`
`
`W0 98/ 19998
`
`PCT/EP97/06125 _
`
`
`
`
`
`258SW:U$22.02”08-8.3:6:8353%a:
`
`.0Z.xm9
`
`”08-8.986:825:0:2w::28:53::Muzzée”08-89:6:832:2:am:a:
`
`
`
`
`
`
`
`€538.5:Q2202$58.3:6:8b6:3:?
`
`
`
`6598.5uEEG:”8636a9:6:82:?
`
`
`
`:33:32“5:26:”cog:9:6:8at:2:3,
`
`
`
`ea“:35”E226:”062-8:9:6:8923:0
`
`
`
`£535.:“:22?6:852%5.08
`
`
`
`:3332$22.02”08.6:9:6:83:?E
`
`
`
`
`
`653«32822-0:”068%as6:8£2:2:?
`
`
`
`Eae:22822.0:563%as6:82:?
`
`6533.5822-0:$3:9:6:88:?
`
`
`
`
`
`:53$3:6:22-02”087:2:66:82:?
`
`
`
`853$.§6:22-02$2-6:.mé6:82:?
`
`
`
`953mm.:2£32.02”0878:3:6:8233
`
`
`
`8:5«22£220:68303386.56:82:?
`
`v—tv—dv-dv—Ilv—lv—v—dw—‘u—‘v—dv—v—tvd
`
`no
`
`no
`
`so
`
`no
`
`so
`
`no
`
`no
`
`no
`
`no
`
`no
`
`no
`
`so
`
`no
`
`so
`
`no
`
`
`
`
`
`8%:oumNtouoEmsu330onszEgan
`
` 953:6.E6:22-02w:2-§.:.56:8£2:2:?_6&3632£22.?6830338as6:8223%_gas$5$22.026:8826-3»:308_acneis822.0:
`
`€889:6:8323:a:”062-6:.956:8333%:98::3.29:22.?
`
`
`1:681:2225Efiiaegigi.2:é
`
`::§:5:&§5§$-~
`
`Eugamxeaqm
`
`Rana—29mg
`
`a...»:EE%§:33§-N
`
`no
`
`no
`
`no
`
`no
`
`no
`
`
`$303956?£6:9:?:_E8:_E8:35£22-02”08$:.956:86:636_Esme2.5822.0::3:822-0:
`
`
`
`EB3:656:385822:fie.fl
`
`::§§€-~§8:E-~-rfirm:
`
`::§:=~:%§E-S-N
`
`$395293
`
`no
`
`so
`
`-2»:2:::3&E-:6.~._Em.mm.m~.m:m:
`
`1-936546:
`
`.EEEE:&§£~E€.m6:
`
`emfiofixcaus93
`
`EBEsagsfimiH
`
`3.5:.“ch
`
`.anasuévfi
`
`325—53520.
`
`15:2—
`
`15683586683
`
`1523686.}
`
`1:315:9N
`
`$359
`
`3::
`
`no
`
`1:821:35563.Ema:
`
`.0ZoEmem
`
`«M
`
`mm
`
`em
`
`hm
`
`an
`
`an
`
`av
`
`5:
`
`NV
`
`ma
`
`36
`
`mu
`
`cw
`
`he
`
`wv
`
`an
`
`mmmam
`
`mm
`
`vm
`
`mm
`
`em
`
`
`
`
`
`WO 98/19998
`
`PCT/EP97/06125 _
`
`3.808H”888,878.02$8.88:8.5”808888888888808288:22-028080-08088.888W8888Om0808a0888836.88808U88.88:80888888088888.888888008580-38.m888888
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`288838880800.8888:88.8028”8278.0:8098.0:.8880M888828883880888.82880
`
`
`
`
`
`
`
`
`
`
`
`_8.8888802.888H”88888.02fl8888Om080888,8088888288838.888888888888808.0
`
`
`
`
`
`
`
`88088888888888888888888808”822.0280808.88.8888.M88883.28883888088.88888888880E.8N8”88278-0:
`
`
`
`
`
`
`
`
`
`
`
`
`2888388808888888808888888880mm.8N8H”888,878.02808888888888288838888V888858589803
`
`
`
`
`
`
`
`
`
`
`
`888888880$808“”88,878.02”8888808088MW088883.880888088888808888
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`880808“N88220:“0388.8888.888”8888828.838888V880-58.888.888.88.8888..m.~m0_888888888@80888822-0:”8.8808030.08.888:88088808888388888-v.:80880888888=08-88M888880
`
`
`
`
`
`
`
`8:030000888088800:03808:868880808mwas:80880888308808:8088018068802»-N.:888.8.».81508080:Eb-m:-N8088wEtfim88
`
`
`
`8:6888868".888”00008880008H.008
`
`
`
`
`
`
`
`
`
`8808880600888388:8u8088880888088008883808:8H80880800830088:8H8
`
`
`
`
`
`
`
`
`
`
`
`088060300006608088808000830888688308808Am8-N._b0000.80_880.H88$88888688838808:86:08:0868808680830880-58880008
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`838%COSMNCDHONHNfimUEma—omofid—PV5.80mMDEENXM
`
`.OZ.xm08.02
`
`803808:86:08080889888808808
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`0:089808wEmsa088888888808888808888088800808808888888008088008808::80888808883088080880888388:80880.5:0880805A1888088808883.58:080000058Moo08880888808088088868880808880880@8000:a8880200008880880
`
`
`
`
`
`
`
`8:0.0808888080860888808000808::0888008080088068888888808800888080888.888888580888088888888508086:0800088:00888086888288:0
`
`
`
`
`
`
`
`
`
`
`
`8030mm08880—8800:03808:86:080808m88368080m00888m:00888888:08000808883888888
`
`
`
`
`
`
`
`
`
`
`
`8:02000858”cm0888088838888:08808:0688808088808800:038088800
`
`
`
`
`
`
`
`8:020000888088800:089:08868080808m6088888.0w8>068003880838080808008.8@8083
`
`
`
`
`
`
`
`
`
`8:080000888088800:03808:86888088.8mwEmssm
`
`
`
`
`
`
`
`8:02000fiomnow0888088838888:08808:8868880808880880053808w:8m88
`
`
`
`
`
`
`
`a.
`
`3Am
`
`
`
`WO 98/19998
`
`PCT/EP97/06125
`
`-15_
`
`28.5:u35:8,EE«22.02#3:385
`A288%was:c5050£2ms”32o:
`A285%3a:m50on55ms542u:
`A285%2a:aszman:3E22o:
`
`A285%8.2~c8050.EEms542u:
`28canmam:c308.523E22u:
`28Ea$1.2u85an:3~32u:
`288%SSSu65£23$2202
`285%8.§c65£23~32u:
`
`”MEZ*
`
`.35ngwEtSmmm«Saw—zoamfinucinofl-3-Ammimiudd95:
`
`
`
`3538wfitfimma_c:au=n-fi-o:_EN-NA+YAmvwas:
`
`3:022:wEtSwmmwEEBfimmoEEa.WEE—on.TTVAKOwas:
`
`38:3:@583mmonanacnuc:ofifia.a-oxo.iimam:
`
`REE:wfitfimmmQEESFEKEéBA¢mafia
`
`
`
`
`
`HESS:mafia;ms158—“_3:3A£5—»:unnemfiuficfifia-uv-Nwas:
`
`HEREmass:3win—«Roanfinuofiaomm.$Y§m£m£~£5was:
`
`REESmagsmm“Engine—«mo-mAaEEaEnEmoEEa$Y~was:
`
`
`
`5335wcmtfimmmo:_.€u:n2c:-3AmN.mSmama:
`
`353E@535mmBEuE-AiAmvmam:
`
`8—aSs
`
`:—
`
`AN—
`
`:2
`
`G—
`
`G—
`
`3—
`
`
`
`W0 98/19998
`
`PCT/EP97/06125
`
`—16—
`
`A285%85:c
`
`5050.EE3E220:
`
`288%35c
`85:523~32v:
`
`288%:3:u
`Sumo£23~32v:
`
`295%mod:c
`80505:23~32on
`
`28EE3m:u
`5060£23~32o:
`
`A285%N326
`65.EE3~32o:
`
`29can~22u
`85am:wt”:22o:
`
`29Ea33:u285%mod:w
`Some”£2wt«22u:
`Bode£23~320:
`
`20v5%wow:u285%mg:n
`5050£23~32u:
`380.EE3E22u:
`
`28Ea85:c
`
`5060.523~52o:
`
`28SEc95:8£56mzzu:
`
`#2:59—80
`
`
`
`WO 98/19998
`
`PCT/EP97/06125 _
`
`-17-
`
`The compounds of the invention in free form or in pharmaceutically acceptable acid
`
`addition salt form, hereinafter briefly named "the agents of the invention", in particular, the
`
`compounds of formula I in free form or in pharmaceutically acceptable acid addition salt form,
`
`possess pharmacological activity. They are therefore indicated for use as pharmaceuticals.
`
`In particular, they inhibit DPP—IV. This activity may be demonstrated employing the
`
`Cac0-2 DPP-IV assay, which measures the ability of test compounds to inhibit DPP-IV
`
`activity from human colonic carcinoma cell extracts. The human colonic carcinoma cell line
`
`Caco-2 can be obtained from the American Type Culture Collection (ATCC HTB 37).
`
`Differentiation of the cells to induce DPP-IV expression is accomplished as described by
`
`Reisher et al. in Proc.Natl.Acad.Sci.USA fl (1993) 5757-5761. Cell extract is prepared from
`
`cells solubilized in 10 mM Tris-HCI, 0.15 M NaCl, 0.04 t.i.u. (trypsin inhibitor unit)
`
`aprotinin, 0.5% non-ionic detergent P40, pH 8.0, which is centrifuged at 35 000 g for 30 min
`
`at 4°C to remove cell debris. The assay is conducted by adding 20 mg solubilized Caco-2
`
`protein, diluted to a final volume of 125 ml in assay buffer (25 mM Tris-HCI pH 7.4, 140 mM
`
`NaCl, 10 mM KCl, 1% bovine serum albumin) to microtiter plate wells. The reaction is
`
`initiated by adding 25ml of 1 mM substrate (H-Alanine~Proline—pNA; pNA is p-nitroaniline).
`
`The reaction is run at room temperature for 10 minutes after which time a 19 ml volume of
`
`25% glacial acetic acid is added to stop the reaction. Test compounds are typically added as
`
`30 m1 additions and the assay buffer volume is reduced to 95 ml. A standard curve of free
`p-nitroaniline is generated using 0-500 mM solutions of free pNA in assay buffer. The curve
`
`generated is linear and is used for interpolation of substrate consumption (catalytic activity in
`
`nmoles substrate cleaved /min). The endpoint is determined by measuring absorbance at
`
`405 nm in a Molecular Devices UV Max microtiter plate reader. The potency of the test
`
`compounds as DPP-IV inhibitors, expressed as IC50, is calculated from 8-point, dose—response
`
`curves using a 4-parameter logistic function.
`
`In the above test, ICso values of from about 10 nM to about 900 nM are obtained with
`
`the agents of the invention, e.g. 22 nM for the agent of Example 3.
`
`The DPP-IV inhibition may also be demonstrated by measuring the effects of test
`
`compounds on DPP-IV activity in human and rat plasma employing a modified version of the
`
`assay described-by Kubota et al. in Clin.Exp.Immunol. 252 (1992) 192—197. Briefly, five ml
`
`of plasma are added to 96—well flat-bottom microtiter plates (Falcon), followed by the addition
`
`
`
`WO 98/19998
`
`PCT/EP97/06125
`
`-18-
`
`of 5 ml of 80 mM MgC12 in incubation buffer (25 mM HEPES, 140 mM NaCl,
`
`1 % RIA—grade BSA, pH 7.8). After a 5 min incubation at room temperature, the reaction is
`
`initiated by the addition of 10 ml of incubation buffer containing 0.1 mM substrate (H—Glycine-
`
`Proline-AMC; AMC is 7-amino—4-methylcoumarin). The plates are covered with aluminum
`
`foil (or kept in the dark) and incubated at room temperature for 20 min. After the 20 min
`
`reaction, fluorescence is measured using a CytoFluor 2350 fluorimeter (Excitation 380 nm
`
`Emission 460 nm; sensitivity setting 4). Test compounds are typically added as 2 ml additions
`
`and the assay buffer volume is reduced to 13 ml. A fluorescence-concentration curve of free
`
`AMC is generated using 0—50 mM solutions of AMC in assay buffer. The curve generated is
`
`linear and is used for interpolation of substrate consumption (catalytic activity in nmoles
`
`substrate cleaved/min). As with the previous assay, the potency of the test compounds as
`
`DPP—IV inhibitors, expressed as ICso, is calculated from 8—point, dose—response curves using a
`
`4 parameter logistic function.
`
`In the above assay, ICso values of from about 7 nM to about 2000 nM are obtained in
`
`human plasma, and of from about 3 nM to about 400 nM in rat plasma, e.g., for the agent of
`
`Example 3, of 7 nM in human and 6 nM in rat plasma, respectively.
`
`In view of their ability to inhibit DPP-IV, the agents of the invention are indicated for
`
`use in treating conditions mediated by DPP-IV. It is expected that the compounds
`
`disclosed herein are useful in the treatment of non-insulin-dependent diabetes mellitus,
`
`arthritis, obesity, and osteoporosis such as calcitonin-osteoporosis. The agents of the
`
`invention improve early insulin response to an oral glucose challenge and, therefore, are
`
`particularly indicated for use in treating non-insulin-dependent diabetes mellitus and
`
`further conditions of impaired glucose tolerance (IGT).
`
`The ability of the agents of the invention to improve early insulin response to an oral
`
`glucose challenge may e. g. be measured in insulin resistant rats according to the following
`
`method:
`
`Male Sprague—Dawley rats that have been fed a high fat diet (saturated fat: 57 %
`
`calories) for 2-3 weeks are fasted for approximately 2 hours on the day of testing, divided
`
`into groups of 8-10, and dosed orally with 10 mmol/kg of the test compounds in '
`
`carboxymethylcellulose (CMC). An oral glucose bolus of 1 g/kg is administered 30 min after
`
`
`
`W0 98/ 19998
`
`PCT/EP97/06125 _
`
`-19-
`
`the test compound directly into the stomach of the test animals. Blood samples, obtained at
`
`various timepoints fro